ArticleFrontiers in oncology2022

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment.

Xugang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.